Meeting
2022 ASCO Annual Meeting
TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.
Authors
Krish Patel
Swedish Cancer Institute, Seattle, WA
Krish Patel , Robert Z. Orlowski , Kimberley Doucette , Michael Maris , Matthew James Pianko , Radhakrishnan Ramchandren , Don A. Stevens , David H. Vesole , Robert A. Uger , Anita Scheuber , Naomi Molloy , Ingmar Bruns , Alexander M. Lesokhin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03530683
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8071)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8071
Abstract #
TPS8071
Poster Bd #
492b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).
First Author: Krish Patel
Poster
2015 ASCO Annual Meeting
A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.
First Author: Jeffrey A. Zonder
Poster
2014 ASCO Annual Meeting
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
First Author: Torben Plesner
Poster
2023 ASCO Annual Meeting
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
First Author: Paul G. Richardson